Related Experiment Video
Updated: May 29, 2026
06:40
Cost-Efficient Transcriptomic-Based Drug Screening
Published on: February 23, 2024
Pharmacogenetics and cost-effectiveness analysis: a two-way street.
Kalipso Chalkidou1, Michael Rawlins
1National Institute for Health and Clinical Excellence, UK. Kalipso.Chalkidou@nice.org.uk
Drug Discovery Today
|September 10, 2011
Summary
Pharmacogenetics uses genetic information to tailor drug treatments. Cost-effectiveness analysis (CEA) can encourage pharmacogenetic test development but may hinder adoption if misused.
Area of Science:
- Pharmacogenetics and Health Economics
Background:
- Genetic and proteomic data identify patient susceptibility and drug response.
- Pharmacogenetics offers personalized medicine approaches.
- Cost-effectiveness analysis (CEA) is crucial for healthcare technology adoption.
Purpose of the Study:
- To review the impact of CEA on pharmacogenetics adoption in healthcare.
- To examine how pharmacogenetics influences CEA methodologies.
- To assess the role of CEA in advancing personalized medicine.
Main Methods:
- Literature review of pharmacogenetics and CEA.
- Analysis of economic incentives and barriers for pharmacogenetic tests.
- Discussion of payer and developer perspectives on CEA.
Main Results:
- CEA can incentivize the development of pharmacogenetic tests.
- Inappropriate use of CEA by payers can hinder technology adoption.
- Ignoring CEA by developers can also impede the integration of beneficial technologies.
Conclusions:
- CEA is a double-edged sword for pharmacogenetics adoption.
- Strategic application of CEA can accelerate personalized medicine.
- Overcoming CEA-related obstacles is vital for realizing pharmacogenetics' full potential.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).